'Disturbing' Disparity in Use of Key Breast Cancer Drug'Disturbing' Disparity in Use of Key Breast Cancer Drug
A study indicates that black patients with HER2+ breast cancer are 25% less likely to receive trastuzumab than are white patients--an underuse that may affect outcomes, reports Dr Lidia Schapira. Medscape Oncology
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Hematology-Oncology Viewpoint Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Hematology | HER2 | Herceptin | Internal Medicine | Study